Implementation of high-dose glucocorticoids and opioid consumption in the first 24 hours after elective hip and knee arthroplasty: a natural experiment study of 47,317 procedures in Eastern Denmark
Preprint
Abstract
Background: In Denmark, high-dose perioperative glucocorticoids were implemented stepwise for patients undergoing total hip arthroplasty (THA), total knee arthroplasty (TKA), and unicompartmental knee arthroplasty (UKA). We aimed to estimate the opioid-sparing effect of adding a single high dose of glucocorticoids to the analgesic regimen. Methods: In this prespecified analysis of a multicentre natural experiment using electronic health record data, we included all elective THA, TKA, or UKA procedures performed in Eastern Denmark from 2017-2025, with no exclusion criteria. At each centre, procedures before implementation of high-dose glucocorticoids served as controls, whereas procedures after implementation comprised the intervention group. A high dose was defined as ≥16 mg or 0.2 mg/kg dexamethasone or ≥80 mg methylprednisolone. The primary outcome was the adjusted between-group difference in 0-24h opioid consumption. The minimal important difference was 5 mg IV morphine equivalents. Secondary outcomes were maximum 0-10 numerical rating scale (NRS) pain score, incidence of opioid-related adverse events, hospital length of stay, and days alive and out of hospital at 30 days. Results: We analysed 47,317 procedures performed at nine centres: 13,010 controls and 34,307 in the intervention group. During the study period, five of nine centres implemented high-dose glucocorticoids for THA patients, two of eight for TKA/UKA patients. High-dose glucocorticoids were administered to 6% and 92% of patients before and after implementation, respectively. The implementation was associated with an adjusted mean reduction of 3.8 mg IV morphine equivalents (95% CI 3.3–4.3) and a 0.8-point lower maximum recorded pain score (99% CI 0.7–0.9) in the first 24 hours, with no statistically significant differences in the remaining outcomes. Conclusions: Implementation of high-dose glucocorticoids was associated with only a small drop in opioid consumption, below the minimal important difference. Key Points Summary: Question : What opioid-sparing effects may be expected when adding high-dose glucocorticoids (≥16 mg or 0.2 mg/kg dexamethasone or ≥80 mg methylprednisolone) to the standard analgesic package for patients undergoing total hip and knee arthroplasty? Findings : In Eastern Denmark, the adoption of high-dose glucocorticoids to the existing multimodal analgesic regimen was associated with a slightly lower 0-to-24 hours in-hospital opioid consumption, according to electronic health record data. Meaning : Clinicians may expect a slightly lower opioid-sparing effect from high-dose glucocorticoids than found in randomised clinical trials.Keywords
Funding Information
- The Danish Society of Anaesthesiology and Intensive Care Medicine (NA)
This publication has 21 references indexed in Scilit:
- Patient‐Related Predictors of Opioid Use, Pain and Opioid‐Related Adverse Events in the First 24 h After Surgery: A Systematic Review and Meta‐AnalysisEuropean journal of pain, 2026
- Real-World Evidence in Drug Approvals at the European Medicines AgencyJAMA Network Open, 2025
- The AI and Automation in Anaesthesia (TRIPLE‐A) Perioperative Database in Eastern Denmark 2017–: A Platform for Epidemiology, AI‐Driven Prediction, Quality Control and Automated Data RetrievalActa Anaesthesiologica Scandinavica, 2025
- The OPI•AID Zone Tool as a composite outcome for postoperative pain management quality—A protocol for an observational pilot studyActa Anaesthesiologica Scandinavica, 2024
- Non-opioid analgesic combinations following total hip arthroplasty (RECIPE): a randomised, placebo-controlled, blinded, multicentre trialThe Lancet Rheumatology, 2024
- Minimal important difference in postoperative morphine consumption after hip and knee arthroplasty using nausea, vomiting, sedation and dizziness as anchorsActa Anaesthesiologica Scandinavica, 2024
- Opioid consumption and non‐opioid multimodal analgesic treatment in pain management trials after hip and knee arthroplasties: A meta‐epidemiological studyActa Anaesthesiologica Scandinavica, 2023
- Systemic glucocorticoids as an adjunct to treatment of postoperative pain after total hip and knee arthroplastyEuropean Journal of Anaesthesiology, 2022
- Corticosteroids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee SocietyThe Journal of Arthroplasty, 2022
- Safety aspects of preoperative high-dose glucocorticoid in primary total knee replacementBritish Journal of Anaesthesia, 2017